Home Solutions of America
( HOM) climbed 13% in late trading Monday after the Dallas-based rebuilding and remodeling services company posted big first-quarter gains and raised its full-year outlook.
Home Solutions posted income of $3.1 million, or 8 cents a share, up from $1 million, or 4 cents a share, from a year ago. Excluding a gain from discontinued operations, earnings were 6 cents a share, matching analysts' mean estimate, according to Thomson First Call. Revenue more than doubled to $19.3 million from $9.3 million.
For 2006, Home Solutions increased its earnings projection to a range of 56 cents to 60 cents a share, up from an earlier view of 42 cents to 46 cents a share. The company sees revenue of $160 million to $165 million, up from its prior guidance of $130 million to $140 million. Home Solutions gained $1.49 to $12.29 in late trading.
rose after the company said that a U.S. district court issued a preliminary injunction against
River's Edge Pharmaceuticals
. The injunction stops River's Edge from selling its niacinamide formula drug as a generic substitute for Dusa's acne drug Nicomide. The court ordered River's Edge to stop making the product, recall it from all wholesalers and distributors and request that it be removed as a generic substitute from the National Drug Data File. Dusa shares rose 5.8% to $7.10 in after-hours trading.
shares tumbled after the
Food and Drug Administration
told the biopharmaceutical company it will have to do more trials for its lead product candidate, DX-88, in hereditary angioedema. The company said in a statement that it will have to "complete some incremental clinical work, most probably a dose-ranging study on subcutaneously administered DX-88 to secure final approval." Dyax said that providing additional data will likely affect the previous projection of an anticipated 2007 regulatory-approval date. Shares fell 27 cents, or 7.8%, to $3.20 after hours.
( COGN) sank after the Ottawa-based software company said it would delay filing its annual report for the year ended Feb. 28 because of an ongoing review by the
Securities and Exchange Commission
. The company said the review relates primarily to how it allocates revenue for post-contract customer support in contracts having multiple elements. Shares slipped $4.94, or 14%, to $29.65 in late trading.
jumped after the Owings Mills, Md.-based maker of weight-and disease-management products reported a big jump in first-quarter earnings. The company posted income of $1.7 million, or 13 cents a share, up from $507,000, or 4 cents a share, a year ago. Revenue rose to 19.2 million from $8.3 million.
Medifast now sees full-year earnings of 38 cents and 40 cents a share on revenue of $66 million to $68 million. This is an increase from its previous guidance for earnings of 29 cents and 32 cents a share, with revenue between $58 million and $60 million. Shares increased $1.60, or 12%, to $14.85 after-hours.